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Several neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), are characterized by the
presence of misfolded proteins, thought to trigger neurotoxicity. Some familial forms of ALS (fALS), clinically
indistinguishable from sporadic ALS (sALS), are linked to superoxide dismutase 1 (SOD1) gene mutations. It
has been shown that the mutant SOD1 misfolds, forms insoluble aggregates and impairs the proteasome.
Using transgenic G93A-SOD1 mice, we found that spinal cord motor neurons, accumulating mutant SOD1
also over-express the small heat shock protein HspB8. Using motor neuronal fALS models, we demonstrated
that HspB8 decreases aggregation and increases mutant SOD1 solubility and clearance, without affecting
wild-type SOD1 turnover. Notably, HspB8 acts on mutant SOD1 even when the proteasome activity is specifi-
cally blocked. The pharmacological blockage of autophagy resulted in a dramatic increase of mutant SOD1
aggregates. Immunoprecipitation studies, performed during autophagic flux blockage, demonstrated that
mutant SOD1 interacts with the HspB8/Bag3/Hsc70/CHIP multiheteromeric complex, known to selectively
activate autophagic removal of misfolded proteins. Thus, HspB8 increases mutant SOD1 clearance via auto-
phagy. Autophagy activation was also observed in lumbar spinal cord of transgenic G93A-SOD1 mice since
several autophago-lysosomal structures were present in affected surviving motor neurons. Finally, we
extended our observation to a different ALS model and demonstrated that HspB8 exerts similar effects on
a truncated version of TDP-43, another protein involved both in fALS and in sALS. Overall, these results indi-
cate that the pharmacological modulation of HspB8 expression in motor neurons may have important impli-
cations to unravel the molecular mechanisms involved both in fALS and in sALS.
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenera-
tive disease characterized by the progressive loss of selected
populations of motor neurons (1). A hallmark of ALS is the
presence of insoluble material, containing proteins involved
in the major intracellular degradative pathways and the
human TAR DNA-binding protein TDP-43 (see below)
(1,2). While the role of these inclusions is largely debated, it
is generally accepted that their formation is linked to protein
misfolding and may alter motor neuronal functions, impacting
on their survival. Thus, by assisting protein folding, it is
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expected to reduce protein aggregation and/or other cascades
of events responsible for motor neuronal cell death in ALS.
More than 80% of ALS cases are sporadic (sALS); among
the rare familial forms (fALS) about one-fifth have been
associated to Cu/Zn superoxide dismutase 1 (SOD1) gene
mutations (3) and even less to mutations in the gene coding
for TDP-43 (a protein found as a major constituent in
inclusions of sALS as well as non-SOD1-fALS) (4,5).
However, since sALS and fALS are clinically indistinguish-
able and mutant SOD1 animal and cellular models have
been developed by different investigators, these models are
widely used to study the disease (1). SOD1 is an essential
enzyme that removes oxidant-free radical species; although
many mutant SOD1s retain their enzymatic activity, a partial
loss of protection from oxygen-free radicals might contribute
to motor neuronal death in SOD1-linked fALS (6).
However, motor neuronal death is apparently mainly due to
a gain of neurotoxic function(s) related to mutant SOD1 mis-
folding (7).
Several studies have demonstrated that chaperones facilitate
the removal of misfolded proteins. Mutations of one of these
chaperones, the small heat shock protein B8 (HspB8, also
called Hsp22) are responsible for distal hereditary motor neu-
ropathy type II (dHMN) (8) and autosomal dominant
Charcot–Marie–Tooth (CMT) disease type 2L (9). Interest-
ingly, HspB8 efficiently removes misfolded proteins contain-
ing elongated polyglutamine tracts (10–12), responsible for
other neurodegenerative diseases (reviewed in 13).
We have thus evaluated, in animal and cellular models,
whether HspB8 may exert a protective role in ALS. The
results indicate that HspB8 expression is upregulated in trans-
genic G93A-SOD1 (tg G93A-SOD1) mice and that HspB8
selectively removes the neurotoxic mutant SOD1 from motor
neuronal cells, restoring normal proteasome activity. This
action is specifically mediated by the activation of the autop-
hagosome–lysosome pathway (APLP). HspB8 also counter-
acts the formation of TDP-43 aggregates. This suggests that
the induction of HspB8 in motor neurons might become a
novel useful target in different forms of ALS.
RESULTS
In the present study, we initially analyzed the role of HspB8
on the solubility, aggregation rate and degradation of mutant
SOD1, responsible for motor neuronal cell death in some
fALS patients. In a second set of experiments, we also
evaluated the effect of HspB8 on TDP-43 solubility and
clearance.
To this purpose, we have taken advantage of the immorta-
lized motor neurons NSC34 cells (14). These cells are
hybrid cells generated by fusion of embryonic motor
neurons with neuroblastoma. We produced NSC34 cells
expressing human SOD1, either wild-type (wtSOD1) or
mutant (G93A-SOD1) to be used as SOD1-linked ALS
models together with transgenic (tg) G93A-SOD1 mice.
Both the NSC34 cells and the G93A-SOD1 mice have been
extensively used in our laboratories to analyze the effects of
misfolded proteins on motor neurons (6,15,16).
Mutant G93A-SOD1 aggregates and impairs the
proteasome in immortalized motor neurons
The NSC34 cells expressing wt or mutant SOD1 have been
analyzed to evaluate differences in the biochemical behavior
of the two proteins. The data (Fig. 1A) show that wtSOD1
localized both in cytoplasm and nucleus and did not form
visible aggregates. Mutant G93A-SOD1 is excluded from
nuclei and forms several large intracellular aggregates. The
amount of insoluble SOD1 species generated in immortalized
motor neurons was quantified in the filter retardation assay
(Fig. 1B) (6,16). In this assay, wtSOD1 was almost undetect-
able both in the basal conditions and after MG132 treatment,
indicating that wtSOD1 did not aggregate even when the pro-
teasome is impaired. Significant amounts of mutant SOD1
were instead retained on the membrane in the basal conditions,
proving that the G93A mutation reduces the protein solubility.
A robust increase of mutant SOD1 accumulation was observed
after MG132 treatment. Western blot analyses (Fig. 1C)
showed that in NSC34 cells expressing wtSOD1, the protein
was in the monomeric form. The levels of wtSOD1 were
only marginally increased in the presence of the proteasome
inhibitor MG132. On the contrary, in NSC34 cells expressing
mutant SOD1, there was a massive decrease of monomeric
forms of this protein, accompanied by the formation of
SDS-resistant, high M.W. species, which could represent
dimeric/oligomeric forms of the misfolded mutant SOD1.
The inhibition of proteasome activity resulted in a much
larger accumulation of monomeric and oligomeric species
(also detectable in the stacking gel). To determine whether
SOD1 aggregates formed in the basal conditions or during pro-
teasome impairment shared some biochemical similarities, we
analyzed the ubiquitination pattern of mutant SOD1 expressed
in NSC34 cells using two experimental approaches. Immuno-
fluorescence microscopy data (Fig. 1D) indicated that mutant
SOD1 aggregates formed in the basal condition were only
marginally ubiquitinated; notably ubiquitin-positive/SOD1-
negative aggregates were visible in several cells expressing
the mutant SOD1. The lack of ubiquitination of mutant
SOD1 aggregates was also confirmed by immunoprecipitation
studies (Supplementary Material, Fig. S1A). These data are in
line with our previous observations obtained using another
protein prone to misfold and to aggregate, the androgen recep-
tor (AR) containing a polyglutamine tract (ARpolyQ) respon-
sible for an ALS-related motor neuronal disease, the spinal
and bulbar muscular atrophy (SBMA or Kennedy’s disease).
In fact, we demonstrated that the ARpolyQ aggregation
process occurs prior to (or independently of) proteasome inac-
tivation (16). Therefore, since the clearance of the insoluble
mutant SOD1 depends on the proteasome, it is expected that
physiological or pathological conditions (oxidative stress,
heat shock, toxic compounds etc.) able to impair proteasome
functions may result in an increased intracellular accumulation
of the abnormal protein, thus worsening the biochemical
behavior of the protein.
To evaluate proteasome activity, NSC34 cells were
co-transfected with SOD1s and the YFPu proteasome reporter
protein (6,16). The results (Fig. 1E and Supplementary
Material, Fig. S1B) showed that YFPu is fully degraded in
immortalized motor neurons expressing wtSOD1, while it
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Figure 1. Biochemical behavior of wt and mutant SOD1 in motor neuronal NSC34 cells. (A) High-resolution fluorescent microscopy analysis on NSC34 cells
transfected with GFP-wtSOD1 or GFP-G93A-SOD1. Upper insets: ×40, lower insets: ×63. Nuclei are stained with DAPI (blue). Scale bars ¼ 10 mm. Arrows
indicate mutant SOD1 aggregates. (B) Filter retardation assays performed on NSC34 cells transfected with wt or mutant G93A-SOD1 in the basal condition or
after treatment with 10 mM of MG132 for 24 h. The histogram is obtained from optical densities of the dots from experiments performed in triplicate (mutant
G93A-SOD1 versus wtSOD1 and wtSOD1+MG132, 8P , 0.01; mutant G93A-SOD1+MG132 versus mutant G93A-SOD1, wtSOD1 and wtSOD1+MG132,
∗P , 0.001). (C) Western blot analyses performed on cell lysates of NSC34 cells transfected with wt or mutant G93A-SOD1 in the basal condition or after
treatment with 10 mM of MG132 for 24 h. hSOD1, human SOD1 monomeric forms; oligomers, dimeric and high-molecular oligomeric species of mutant
SOD1; stacking gel, SDS resistant mutant G93A-SOD1 species. (D) High-resolution fluorescence microscopy analysis performed on NSC34 cells transfected
with GFP-G93A-SOD1 in the basal condition or after treatment with 10 mM of MG132 for 24 h and analyzed at ×63 (scale bar ¼ 10mm). (E) Western blot
assay performed on NSC34 cells transfected with wtSOD1 or G93A-SOD1 and YFPu. NT, untransfected cells.
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Figure 2. Effects of stress conditions on the HspB8 gene expression in motor neuronal NSC34 cells. (A) RT–PCR analysis to evaluate endogenous HspB8
expression in NSC34 cells. Analysis was performed on total RNA of control cultured myoblast cell line (C2C12) or motor neurons (NSC34). 456bp, HspB8
amplicon; H2O, sample without RNA, 2RT, sample without the RT-MMLV. (B) Western blot assay performed on NSC34 cells grown: in the basal conditions:
basal, with proteasome inhibition: MG132 (10 mM for 24 h), with serum deprivation: starvation, exposed to heat shock: shock 428C for 1 h. (C) Transcriptional
activation of the HspB8 promoter (promB8): basal condition: 378C, heat shock at 428C: 428C, serum deprivation: Strv; pGL3-enh: basal vector lacking the
HspB8 promoter. Data are expressed as firefly luciferase activity (count per seconds, CPS) normalized by b-galactosidase activity (Miller Units, MU):
∗pGL3-enh 378C versus promB8 378C, 428C and Strv, P , 0.001. (D) Effect of proteasome inhibition on the transcriptional activation of HspB8 promoter.
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accumulated in cells expressing mutant SOD1, proving protea-
some impairment in these cells. As expected, YFPu accumu-
lation was greatly enhanced after MG132 treatment in cells
expressing either wtSOD1 or mutant SOD1 (Supplementary
Material, Fig. S1B).
Proteasome impairment activates HspB8 expression in
immortalized motor neurons
The intracellular response to misfolded proteins is known to
activate the chaperone systems, with the involvement of
both classical heat shock proteins (Hsp70, Hsp40 etc.) and
small Hsps (HspB1, HspB8 etc). The small Hsps are extremely
interesting, since mutant forms of HspB1 and HspB8 have
been associated with different forms of CMT type 2 disease
as well as distal neuropathies (8,9,17), and the co-chaperone
Bag3, the major HspB8 interactor, has been found mutated
in muscular dystrophy/peripheral neuropathy (18). Moreover,
HspB8 counteracts the aggregation of proteins responsible
for polyQ-related neurodegenerative diseases (10). Based on
these observations, we have analyzed whether HspB8 may
be involved in the intracellular response to SOD1 neurotoxi-
city. We initially demonstrated that HspB8 is expressed in
immortalized motor neuronal cells. In fact, the HspB8
mRNA was detectable (Fig. 2A) and correctly translated
(Fig. 2B) in NSC34 cells. We also tested whether stressful cel-
lular conditions, possibly implicated in sensitizing motor
neurons to protein toxicity in ALS, might modify HspB8
expression levels (Fig. 2B). Serum starvation only marginally
altered the HspB8 levels; greater effect was observed after
heat shock. Generally, this small Hsp is poorly activated by
these two insults (11,19). Interestingly, HspB8 levels dramati-
cally increased when proteasome was impaired (with MG132),
and proteasome impairment is a classical condition occurring
in ALS. The HspB8 increase may depend on its accumulation
(i.e. reduced degradation) or on increased gene expression
(due to perturbations of the general degradative capability of
the cells) (11,19). Thus, we analyzed the HspB8 promoter
activity in NSC34 cells using the promB8 construct. Heat
shock (428C) or serum starvation did not modify the basal
transcriptional activation of HspB8 promoter (Fig. 2C).
Thus, the increased level of the HspB8 protein following
heat shock was due at least in part to its reduced degradation
(competition with the intracellular misfolded protein appeared
after heat shock for degradation?). To determine if increased
synthesis contributed to heat shock-induced elevation of
HSPB8 promoter activity was assessed using the dual lucifer-
ase system (20), because the b-galactosidase levels used in the
previous experiments are heavily affected by the MG132. A
considerably high activation of HspB8 promoter was detect-
able in MG132-treated cells (5-fold over the constitutive pro-
moter activity) (Fig. 2D). Thus, the accumulation of the
HspB8 protein (Fig. 2B) is not only due to its reduced
degradation, but also to a robust increase of its synthesis.
The data were validated by measuring HspB8 mRNA in real-
time PCR (Fig. 2E) and protein in immunocytochemistry
(ICC) (Fig. 2F); both assays confirmed that HspB8 mRNA
and protein levels are increased during proteasome inhibition.
Since proteasome inhibition induces HspB8 expression and
mutant SOD1 over-expression results in proteasome inhibition
(Fig. 1D), we analyzed the effect of mutant SOD1 on HspB8
mRNA levels in transiently or stably transfected (doxycycline
inducible NSC34 cells, kindly obtained from M.T. Carrı`, Uni-
versity of Roma ‘Tor Vergata’) cells. We found that, even if
HspB8 mRNA expression tended to increase in the presence
of the SOD1 enzyme, the protein levels were not significantly
affected (Fig. 2G and Supplementary Material, Fig. S2) by
SOD1s. This may also be due to the different expression
system utilized.
Mutant G93A-SOD1 induces HspB8 expression in spinal
cord motor neurons
We have therefore analyzed the levels of HspB8 mRNA and
protein in mice models of ALS.
Initially, we analyzed possible variations of HspB8 mRNA
in the spinal cord of non-transgenic (non-tg), tg wtSOD1 and
tg G93A-SOD1 mice at three different disease stages: pre-
symptomatic (PS), clinical symptomatic stage (CS) and end
stage (ES). The real-time PCR (Fig. 3A) shows that HspB8
expression slightly declined with age in non-tg mice, being
significantly lower at the oldest age (agES) corresponding to
ES in tg G93A-SOD1 mice. No significant variations of
HspB8 mRNA expression were present in tg wtSOD1 mice
at all ages considered. Interestingly, an induction of HspB8
mRNA expression was detectable in ES tg G93A-SOD1
mice compared with PS or CS tg G93A-SOD1 mice, and to
the corresponding agES tg wtSOD1 mice. Overall, the data
strongly suggest that a partial de-protection against neurotoxi-
city of the misfolded proteins might take place with the aging
processes in normal animals, since the levels of HspB8
decrease in adulthood. However, a considerable response to
the presence of mutant SOD1 was activated in older
animals, indicating that spinal cord cells tended to improve
their ability to respond to misfolded proteins, in line with
data obtained in NSC34 cells in which proteasome impairment
induced HspB8 over-expression.
Immunohistochemistry analysis of the HspB8 protein
showed a weak and diffuse staining in lumbar spinal cord sec-
tions of non-tg and tg wtSOD1 mice at all ages (Fig. 3Ba–f,
and Supplementary Material, Fig. S3A and B). In ES tg
G93A-SOD1 mice, an intense labeling was evident, particu-
larly in the ventral horn, in areas containing the lateral and
medial motor neuronal pools, in white matter and in the
ventral root exit zone (Fig. 3Bg). This was confirmed at
higher magnification where motor neurons can be better
The data reported are expressed as firefly luciferase activity normalized by renilla luciferase activity. ∗promB8 versus promB8+MG132, P , 0.001. (E) Real-
time PCR on endogenous HspB8 mRNA in motor neurons with or without 24 h of proteasome inhibition (∗P , 0.001). (F) Immunofluorescence analysis on
endogenous HspB8 in motor neurons with or without 24 h of proteasome inhibition. Images taken at ×10 (scale bar ¼ 10mm). (G) Real-time PCR showing
the effects of wt and G93A-SOD1 expression on endogenous HspB8 mRNA levels in motor neurons. Mock, NSC34 transfected with pcDNA3; wtSOD1,
NSC34 transfected with pcDNA3-wtSOD1; G93A-SOD1, NSC34 transfected with pcDNA3-G93A-SOD1.
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Figure 3. HspB8 expression in an animal model of ALS. (A) Real-time PCR on HspB8 mRNA expression levels in lumbar spinal cord of non-tg mice, tg wt
SOD1 mice and tg G93A-SOD1 mice. ag, age-matched non-tg mice or tg wt SOD1 mice compared with tg G93A-SOD1 mice [PS animals (11 weeks); CS,
clinical symptomatic stage (18 weeks); ES (24 weeks)]. Non-tg mice agES versus non-tg mice agPS, ∗P , 0.05; tg G93A-SOD1 mice ES versus tg wtSOD1
mice agCS, 8P, 0.001; versus tg wtSOD1 mice agPS, agES and tg G93A-SOD1 mice PS, §P , 0.01; tg G93A-SOD1 mice ES versus tg G93A-SOD1 mice
CS (#P , 0.05). (B) Immunohistochemical localization of HspB8 in lumbar spinal cord sections of non-tg mice (a–c) and of tg wtSOD1 mice (d–f) or tg
G93A-SOD1 mice (g–i) at 22 weeks of age (ES). Figures (a), (d) and (g) are low magnifications of spinal cord hemisections (dh, dorsal horn; vh, ventral
horn; scale bar ¼ 27 mm); figures (b), (e) and (h) are details of the ventral horn (scale bar ¼ 10 mm) and figures (c), (f) and (i) are high magnifications of
motor neurons (scale bar ¼ 4 mm). Arrows point to labeled motor neurons. In control, non-tg and tg wtSOD1 mice HspB8 is weekly expressed in the spinal
cord (a and d) and motor neurons (arrows in b, c, e and f) display only a faint immunoreactivity in their soma and proximal dendrites. In tg G93A-SOD1
mice (g–i), HspB8 is more intensely expressed compared with controls and it is evident in the neuropil of ventral horn, in the soma and proximal dendrites
of motor neurons (arrows in h and i), in motor neuronal axons (arrowheads in g and h point to the ventral root exit area) and in the white matter (wm).
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appreciated (Fig. 3Bb, c, e, f, h, i). Motor neurons of control
non-tg and tg wtSOD1 mice showed only a faint labeling in
their soma and proximal dendrites (Fig. 3Bb, c, e, f and Sup-
plementary Material, Fig. S3A and B), whereas in the ventral
spinal cord of tg G93A-SOD1 mice HspB8 immunoreactivity
was present both in the neuropil and in the soma and proximal
dendrites of motor neurons (Fig. 3Bh and i). In spinal cord sec-
tions of PS and CS tg G93A-SOD1 mice, only a moderate
increase in HspB8 immunoreactivity was found in ventral
horn compared with controls (Supplementary Material,
Fig. S3A–D).
The possible co-localization of mutant SOD1 with HspB8 in
the lumbar spinal cord was analyzed in immunofluorescence
confocal microscopy. In line with the immunoperoxidase
data (Fig. 3), HspB8 was poorly expressed in motor neurons
of tg wtSOD1 mice (Fig. 4A–A′), whereas in tg
G93A-SOD1 mice at PS age, HspB8 labeling was intense
only in motor neurons accumulating human SOD1, and
weak in motor neurons containing low levels of human
SOD1 (Fig. 4B–B′). In tg G93A-SOD1 mice at ES, HspB8
was intensely expressed in several motor neurons containing
human SOD1 and also in the neuropil (Fig. 4C–C′). More-
over, immunofluorescence double-labeling with anti-GFAP
to visualize astrocytes showed that only in spinal cord sections
of ES tg G93A-SOD1 mice the reactive astrocytes in ventral
gray and white matter also expressed HspB8 (Fig. 4D–E).
On the contrary, microglial cells identified with the lectin
LEA did not express HspB8 (Supplementary Material,
Fig. S3E).
These data support the idea that HspB8 is over-expressed
selectively in motor neurons that are more sensitive to
mutant SOD1 neurotoxicity and in the numerous activated
astroglial cells present only in ES tg G93A-SOD1 mice.
Thus, the lack of a detectable increase in HspB8 mRNA
levels at the PS stage (Fig. 3A) could be explained by a
restricted increase of HspB8 expression in motor neurons,
undetectable in real-time PCR performed on whole spinal
cord samples.
HspB8 expression increases the clearance and removes
mutant G93A-SOD1 oligomers and aggregates in
immortalized motor neurons via a
proteasome-independent pathway
Because of the biological action of chaperone proteins, we
tested the possibility that HspB8 modifies the mutant SOD1
solubility, the aggregation rate and/or the ability of the protea-
some to remove insoluble species in NSC34 cells
co-expressing wt or mutant SOD1 and HspB8. Fluorescence
analysis (Fig. 5A) showed that, in the basal conditions,
mutant SOD1 formed intracellular aggregates that are comple-
tely removed by HspB8; a massive decrease of mutant SOD1
protein levels was also detectable, suggesting that this chaper-
one activates SOD1 degradation. Moreover, while the levels of
mutant SOD1 were negligible in HspB8-expressing motor
neurons, no variations in the levels and cellular distribution
of wtSOD1 were detectable (Fig. 5A). The quantitative analy-
sis (Table 1 in Fig. 5B) showed that HspB8 expression reduced
both the total number of cells containing aggregates and the
mean aggregates per cell.
Figure 5C shows the effects of HspB8 on the solubility of
mutant SOD1 in immortalized motor neurons. The over-
expression of HspB8 completely removed SDS-resistant high
M.W. oligomers of mutant SOD1 and increased the clearance
of the full-length mutant monomer. Interestingly, HspB8 also
efficiently acted on mutant SOD1 expressed in NSC34 cells
with MG132-induced proteasome impairment. Similar data
were obtained by measuring the total levels of insoluble
mutant SOD1 by filter retardation assay (Fig. 5C, bottom
inset). In fact, HspB8 efficiently counteracted the formation
of the total amount of mutant SOD1 insoluble species,
confirming that the mutant misfolded SOD1 protein is
cleared by an intracellular degradative system in an HspB8-
dependent/proteasome-independent manner.
The analysis of the biochemical behavior of mutant SOD1
insoluble aggregates tested in buffers with increasing deter-
gent properties showed that HspB8 over-expression almost
completely counteracted the formation of all types of mutant
SOD1 insoluble species (PBS-, Triton-, SDS- and Formic
Acid-resistant) both the monomeric and high M.W. species
(Supplementary Material, Fig. S4A–D). These data further
support the notion that HspB8 acts also when proteasome is
impaired. In fact, it clearly appears both from Fig. 5C and D
and Supplementary Material, Fig S4 that most of the
detergent-resistant high M.W. species were removed by
HspB8 even in the presence of MG132. Interestingly, when
the proteasome was inhibited by MG132, the HspB8 was
found in a triton-resistant, SDS soluble form (Supplementary
Material, Fig. S4C). The biological meaning of this obser-
vation remains to be elucidated. These effects were not due
to HspB8-induced modifications of cell growth and survival,
since cell viability tests showed no variation in NSC34 cells
over-expressing HspB8 and wt or mutant SOD1 (Supplemen-
tary Material, Fig. S5). Moreover, the data also demonstrated
that HspB8 over-expression facilitated the clearance of the
misfolded protein, without generating neurotoxic (oligo/etero-
meric) species from mutant SOD1 aggregate processing. Cell
viability data also exclude compensatory mechanisms generat-
ing excessive activation of deleterious processes (i.e. autopha-
gic cell death/cell self-cannibalism and apoptotic mechanisms,
both reported in neurodegeneration).
The effect of HspB8 on proteasome activity in
G93A-SOD1/NSC34 cells is shown in Figure 5D. In NSC34
cells expressing mutant SOD1, YFPu accumulation was com-
pletely counteracted by the contemporary expression of
HspB8, an effect evident also in the presence of MG132.
Thus, HspB8-induced mutant SOD1 solubility did not affect
proteasome activity in immortalized motor neurons (as it
may be expected by the increased amount of the misfolded
proteins to be processed).
Therefore, we wanted to evaluate whether the HspB8 action
on the mutant SOD1 protein is specifically mediated by its
chaperone properties. To this purpose, we have taken advan-
tage of the existence of two HspB8 mutants (K141N or
K141E); these HspB8 mutants are associated with the devel-
opment of HMN and/or CMT (8,9) and characterized by a
marked reduction of their chaperone activity. We initially
evaluated the effects of either wt or mutant HspB8s on the
total levels of mutant SOD1 by using a GFP-tagged
G93A-SOD1 in flow cytofluorimetric analysis. The results
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Figure 4. HspB8, G93A-SOD1 and GFAP localization in the lumbar spinal cord of a mouse model of ALS. (A–C′) HspB8 and G93A-SOD1 in anterior horn
motor neurons. Immunofluorescent localization of HspB8 (green) and human SOD1 (red) in ventral lumbar spinal cord sections of age-matched ES tg wtSOD1
mice (A–A′) and of pre-symptomatic (PS, B–B′) and ES (C–C′) tg G93A-SOD1 mice. In tg wtSOD1 mice (A–A′), HspB8 is weekly expressed in the soma and
proximal dendrites of motor neurons containing moderate amounts of SOD1 (arrows). In tg G93A-SOD1 mice at PS (b–b′), HspB8 is intensely expressed only in
motor neurons containing human SOD1 (arrows) and weekly expressed in motor neurons (asterisks) not containing human SOD1. In tg G93A-SOD1 mice at ES
(C–C′), HspB8 is intensely expressed in several motor neurons containing human SOD1 (arrows) and also in the neuropil. Scale bar ¼ 3 mm. (D–E′) HspB8 and
GFAP in ventral spinal cord. Both in the gray matter (D–D′) and in the white matter (E–E′) some GFAP-labeled astrocytic processes (arrows) and cell bodies
(arrowhead) express HspB8 immunoreactivity. N, HspB8-positive motor neuron. Scale bar ¼ 2 mm.
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(Fig. 5E) demonstrate that HspB8 greatly reduced the total
levels of GFP-G93A-SOD1 (P , 0.001). When K141E or
K141N variants of HspB8 were used, the total levels of
mutant GFP-G93A-SOD1 remained unchanged, and the
effect of wtHspB8 was lost (P, 0.001). To prove that the
chaperone activity is specifically directed toward misfolded
SOD1 forms prone to aggregation, we have analyzed the
effects of the same HspB8 variants on the insoluble mutant
SOD1 species trapped by cellulose acetate membranes in a
filter retardation assay. The results (Fig. 5F) demonstrate
that only the wtHspB8, which retains its chaperone activity,
counteracted the formation of mutant SOD1 insoluble
species in immortalized motor neurons; instead, comparable
levels of insoluble mutant GFP-G93A-SOD1 aggregates
were present in mock transfected NSC34 cells and in those
expressing HspB8 K141 mutants lacking the chaperone
activity. The data strongly suggest that HspB8 chaperone
activity is absolutely required to remove mutant SOD1 from
our immortalized motor neuronal NSC34 cells.
HspB8 induces mutant G93A-SOD1 clearance by
activating the autophagosome–lysosome pathway
Since the HspB8-dependent removal of insoluble forms of
mutant SOD1 does not require a functional proteasome, we
further analyzed whether the autophagic system might be the
cellular pathway responsible for the beneficial effects of
HspB8 on misfolded proteins involved in ALS. In fact, there
are consistent molecular evidences demonstrating that APLP
removes aggregated proteins (21), and HspB8, after inter-
action with Bag3, activates autophagy (11,19,22,23,36). We
thus evaluated the effects of HspB8 on the clearance of the
misfolded mutant SOD1 via the APLP (24). Initially, we ana-
lysed HspB8 activation of APLP by electron miscroscopy in
NSC34 cells. In the cytoplasm of NSC34 cells expressing
HspB8 together with G93A-SOD1 (Fig. 6Aa–c) or wtSOD1
(Supplementary Material, Fig. S6A–C), we detected numer-
ous vesicles of different sizes surrounded by a double
membrane, thus identifiable as autophagosomes, which were
absent in NSC34 cells without HspB8. Moreover, electron
microscopy of the ventral spinal cord of ES tg G93A-
SOD1 mice revealed the presence of intraneuronal
autophagosome-like vesicles (Fig. 6Ad and e), whereas
motor neurons of agES tg wtSOD1 mice contained only
lypofuscin (Supplementary Material, Fig. S6D and E). This
Figure 5. Effects of HspB8 on mutant G93A-SOD1 aggregation, solubility and
degradation, as well as on proteasome functions in motor neuronal NSC34
cells. (A) Fluorescent microscopy (40×) analysis on motor neurons expressing
HspB8 and either GFP-wtSOD1 or GFP-G93A-SOD1. Scale bar ¼ 10mm. (B)
Quantification of HspB8 effects on the number of SOD1 aggregates in NSC34
cells. Number of SOD1 aggregates positive cells basal versus +HspB8, ∗P ,
0.0001; mean SOD1 aggregates number per cell basal versus +HspB8,
8P , 0.00001. (C) Western blot analyses (top) on NSC34 expressing HspB8
and either wt or G93A-SOD1s with or without proteasome inhibition.
hSOD1, human SOD1 monomeric forms; mSOD1, mouse SOD1; oligomers,
mutant SOD1 dimeric and high molecular weight (MW) species. Filter retar-
dation assay (bottom) performed on the same samples. (D) Western blot assay
on NSC34 cells expressing G93A-SOD1 and YFPu with or without HspB8 and
24 h of proteasome inhibition. (E) Flow cytofluorimetric analysis performed
on NSC34 expressing GFP tagged mutant G93A-SOD1 (GFP-G93A-SOD1)
alone or co-transfected with either HspB8 or mutant HspB8 lacking chaperone
activity (HspB8 carrying the K141E or K141N mutations)
(GFP-G93A-SOD1+HspB8 versus GFP-G93A-SOD1, ∗P , 0.001;
GFP-G93A-SOD1+HspB8_K141E or K141N versus GFP-G93A-SOD1+
HspB8, 8P , 0.001). (F) Filter retardation assays performed on NSC34 cells
co-transfected with wt or mutant GFP-G93A-SOD1 and either the wtHspB8
or the HspB8 carrying the K141E or K141N mutations.
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Figure 6. Effects of HspB8 on autophagic marker accumulation in motor neuronal NSC34 cells. (A) Ultrastructural detection of autophagic structures in NSC34
cells transfected with G93A-SOD1 and HspB8 (a–c) and in lumbar spinal cord sections of tg G93A-SOD1 mice at ES (d and e). The cytoplasm of NSC34
double-transfected cells contains several vesicles of different sizes surrounded by a double membrane (arrows); Nu, nucleus. Scale bars ¼ 0.5 mm in (a) and
(c); 0.2 mm in (b). The cytoplasm of neuronal profiles in ES tg G93A-SOD1 mice contains vacuoles surrounded by a double membrane (arrows) dispersed
among aggregates of electron-dense material and whorls of membrane-like structures (asterisks). Scale bars ¼ 2 mm in (d); 1 mm in (e). (B) Flow cytofluori-
metric analysis performed on NSC34 cells expressing GFP-LC3 and either wtSOD1 or mutant G93A-SOD1. Cells have been synchronized at APLP for 15 h
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suggests that surviving motor neurons in fALS mice can
activate autophagy.
Fluorescence microscopy (Supplementary Material, Fig. S7)
showed that HspB8 over-expression greatly accelerates LC3
turnover, as indicated by a general decrease of transfected
GFP-LC3 in the vast majority of NSC34 cells (upper insets).
At higher resolution, the NSC34 cells expressing HspB8 and
still containing fluorescence showed the classical intense LC3
punctate distribution, proving that this autophagic marker is
bound to the autophagosome membrane as an LC3-II lipidated
isoform. On the contrary, GFP-LC3 cells not expressing
HspB8 showed a more intense, but diffuse cytoplasmic distri-
bution of the fluorescence, indicating that in this condition the
autophagic marker is in the soluble LC3-I inactive form, not
bound to autophagosome membranes.
To quantify the effect of HspB8 on autophagy and to further
characterize the APLP involvement in ALS models, we
adopted a bafilomycin-synchronized APLP protocol (24) to
measure, by flow cytofluorimetric analysis, LC3 turnover in
a limited time window of observation. The experiments
(Fig. 6B and C) performed on G93A-SOD1 NSC34 cells
showed that HspB8 dramatically decreased the intracellular
levels of LC3, in only 3 h of active APLP. To prove that
HspB8 acts via the APLP system, we performed filter retar-
dation assays on cell lysates of NSC34 cells expressing
mutant GFP-G93A-SOD1 and treated with the APLP inhibitor
bafilomycin (Fig. 6C). The data confirmed that HspB8 induced
a dramatic reduction (about 5–6-fold) of the total insoluble
species even in the presence of MG132. The results demon-
strated that bafilomycin counteracted the HspB8-induced
clearance of the insoluble species formed by the misfolded
mutant SOD1 protein. We further investigated the potential
mechanism of action of HspB8 in activating mutant SOD1
degradation via autophagy, by looking at possible interactions
between the two proteins. Surprisingly, immunoprecipitation
studies, using an anti-SOD1 antibody, showed that in the
basal condition HspB8 did not directly interact with SOD1
(Supplementary Material, Fig. S8A). In MG132-treated
NSC34 cells, SOD1 enzymes co-immunoprecipitated with
small amounts of HspB8 (Supplementary Material,
Fig. S8B). This suggests that the perturbation of the ubiquitin-
proteasome pathway may result in a general accumulation of
the HspB8 client proteins to be degraded.
We thus postulated that the lack of interaction between
mutant SOD1 and HspB8 could be due to the fast degradation
of the mutant SOD1 when it is recognized by the HspB8, since
HspB8 efficiently targets mutant SOD1 for autophagic clear-
ance. Obviously, because of its nature, the mutant SOD1/
HspB8 complex will be characterized by a very short half-life,
being quickly removed by autophagy. We thus speculated that
a blockage of autophagy should induce accumulation of the
HspB8/SOD1 complex. To this purpose, we adopted different
experimental paradigms in which (i) we blocked autophagy
initiation using 3-MA, to try to prevent HspB8/SOD1 dis-
sociation and degradation, (ii) we allowed autophagy
initiation, but blocked autophagosome–lysosome full acti-
vation using bafilomycin. This might allow the release of
mutant SOD1 from HspB8, and its insertion into the autopha-
gic machinery. The results obtained (Fig. 6D) perfectly
overlap our working model. In fact, when autophagy-mediated
clearance of mutant SOD1 was pharmacologically blocked
with 3-MA, we were able to detect co-immunoprecipitation
of mutant SOD1 with HspB8. We also included in this analy-
sis the immunodetection of Bag3, Hsc70 and CHIP. In fact, it
has very recently been demonstrated that misfolded proteins
are recognized by HspB8 and then inserted in a multihetero-
meric complex, which includes HspB8, Bag3, Hsc70 and
CHIP, that allow p62 recognition of the target protein and
the formation of the autophagosome (25). The immunoprecipi-
tation performed using an anti-SOD1 antibody on untreated
3-MA- or bafilomycin-treated NSC34 neurons expressing
mutant SOD1 showed the presence of a faint band of HspB8
or of Bag3 in the basal conditions, when misfolded SOD1
was recognized and immediately targeted for autophagic
degradation. Autophagy blockage with 3-MA prevents autop-
hagosome assembly, and misfolded mutant SOD1 cannot be
inserted into the autophagosome. The misfolded SOD1 was
not cleared from the cell and co-immunoprecipitated with
HspB8, Bag3, Hsc70 and CHIP, in the multiheteromeric
complex required for misfolded protein insertion into the
autophagosome.
Autophagy blockage with bafilomycin did not prevent the
autophagosome assembly. In these conditions, the misfolded
mutant SOD1 can be inserted into the autophagosome, and is
obviously released from the HspB8/Bag3/Hsc70/CHIP
complex. Since all these proteins co-immunoprecipitate with
misfolded SOD1 when its insertion into the autophagosome is
prevented with 3-MA, HspB8 activity in motor neurons is
directly responsible for autophagic removal of mutant SOD1.
Since HspB8 over-expression is sufficient to re-activate
mutant SOD1 autophagic clearance, the HspB8 in this view
might act as a limiting factor of the entire degradative pathway.
HspB8 chaperone effects assist the removal of TDP-43
insoluble species and aggregates via autophagy
Recently, most sALS and several fALS have been linked to
the presence of inclusions positive for the TDP-43 protein
using 10 nM of bafilomycin, which was removed 3 h prior to the analysis (mock versus mock+HspB8, wtSOD1 versus wtSOD1+HspB8, ∗P , 0.001;
G93A-SOD1 versus G93A-SOD1 + HspB8, 8P, 0.01). (C) Filter retardation assays on NSC34 cells expressing mutant GFP-G93A-SOD1 in the absence or
presence of HspB8, in the basal condition or after treatment with 10 mM of MG132 for 24 h, or 10 nM of Bafilomycin for 24 h. The histogram represents a quanti-
fication of the filter retardation assay (from three different replicates) (∗P , 0.001, +HspB8 versus 2HspB8; §P, 0.001, +Mg132+HspB8 versus +Mg132;
8P , 0.001, +HspB8+bafilo versus +HspB8). (D) Analysis of the interaction between mutant SOD1s and HspB8 in immortalized motor neurons during autop-
hagy blockage. Western blot analysis is performed on SOD1 immunoprecipitated samples obtained from untransfected NSC34 or NSC34 expressing mutant
G93A-SOD1 in the presence of HspB8. The blot was subsequently processed using an anti-SOD1 antibody and after stripping processed with anti-c-myc anti-
body recognizing transfected HspB8, anti-Bag3 antibody, anti-Hsc70 antibody and finally anti-CHIP antibody (the antibodies against Bag3, Hsc70, CHIP recog-
nize the endogenous mouse proteins). Treatments were performed using 10 mM 3-MA for 24 h or 10 nM of bafilomycin for 24 h. It appears that a faint band of
HspB8 is present in immunoprecipitated samples of mutant SOD1 in the basal conditions. Inhibition of autophagosome formation with 3-MA, resulted in a dra-
matic accumulation of the complex known to mediate the HspB8 action through autophagy: HspB8-Bag3-Hsc70-CHIP.
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Figure 7. Effects of HspB8 on FL TDP-43 and DC TDP-43 subcellular localization, aggregation and solubility in motor neuronal NSC34 cells. (A) Immuno-
fluorescence analysis (×40) on NSC34 cells expressing either FLAG-tagged FL TDP-43 or DC TDP-43 and HspB8. Arrows indicate DC TDP-43 cytoplasmic
aggregates. Scale bar ¼ 10 mm. (B) Western blot and filter retardation assays on NSC34 expressing either FLAG-tagged FL TDP-43 or DC TDP-43 and HspB8.
FL TDP-43 ¼ human full-length TDP-43 monomeric forms; DC TDP-43, human C-terminus truncated TDP-43 monomeric forms; oligomers, dimeric/high MW
species of DC TDP-43; NT, non-transfected cells; mock, NSC34 transfected with the empty vector. The histogram represents a quantification of the filter retar-
dation assay (from three different replicates). (C) Flow cytofluorimetric analysis performed on NSC34 cells expressing GFP-LC3 and either FL TDP-43 or DC
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(2,5); TDP-43 mutations (mainly C-terminal) have been
identified in ALS (4). These are all missense mutations, but
one frameshift mutation creates a premature stop codon
(p.Y374X) that generates a C-terminal truncated TDP-43
protein (26,27). In post-mortem samples of sALS patients,
inclusions contain the TDP-43 C-terminus (2), but both
N- and C-terminal TDP-43 fragments aggregate in neuronal
cell cultures (28), and might be involved in triggering aberrant
protein folding (28,29). The C-terminus retains TDP-43 into
the nucleus, is essential for solubility and cellular localization,
and its deletion results in the formation of large nuclear and
cytoplasmic aggregates (29). Taking advantage of this
system, we evaluated whether HspB8 counteracts TDP-43
misfolding and aggregation induced by the removal of the
C-terminal region of the protein (DC TDP-43). The results
in Figure 7A show the intracellular localization of the full-
length TDP-43 (FL TDP-43), compared with DC TDP-43.
While the FL TDP-43 was exclusively localized into nuclei,
the DC TDP-43 was present in the nucleus (29,30) and aggre-
gated in the cytoplasm. HspB8 did not modify the behavior of
FL TPD-43, while it completely removed DC TDP-43 from
the cells, suggesting that it could activate the degradation of
the aberrant DC TDP-43 conformations. Moreover, DC
TDP-43 formed oligomeric species migrating at higher
M.W. that were almost completely removed by HspB8
expression (Fig. 7B). Only negligible levels of the truncated
monomeric protein remained detectable. Finally, filter retar-
dation analysis demonstrated that HspB8 over-expression
also greatly reduced the total amounts of insoluble DC
TDP-43. Overall, these data indicated that HspB8 is active
also against DC TDP-43 involved in different types of ALS.
We quantified the effect of HspB8 on autophagy using the
bafilomycin-synchronized APLP protocol described above to
measure, by flow cytofluorimetric analysis, the LC3 turnover
also in the TDP-43 ALS model. The data (Fig. 7C) showed
that HspB8 dramatically decreases the intracellular levels of
LC3, in only 3 h of active APLP. As in the case of mutant
SOD1, filter retardation assays demonstrated that HspB8 acts
via the APLP system also in the case of TDP-43. In fact, bafi-
lomycin treatment counteracted the HspB8-induced clearance
of the insoluble species formed by the misfolded fragment of
the TDP-43 proteins in cell lysates of NSC34 cells expressing
the DC TDP-43 (Fig. 7D).
DISCUSSION
In the present study, we found that mutant G93A-SOD1 aggre-
gates and impairs the proteasome system in a motor neuronal
model of fALS represented by G93A-SOD1 NSC34 cells.
The proteasome impairment correlates with an increased
expression of the chaperone protein HspB8. We also found
that HspB8 is already over expressed in a few lumbar motor
neurons of PS tg G93A-SOD1 mice that also express high
levels of mutant SOD1. This phenomenon become more
evident and involves many more motor neurons, and also
astrocytes, with disease progression until the ES. This is in
line with previous results showing in two-dimensional immu-
noblot a progressive increase of detergent insoluble human
SOD1 partially ubiquitinated in the spinal cord of tg G93A-
SOD1 mice, but not in wtSOD1 mice (31). Thus, the
expression pattern of HspB8 correlates with the progressive
accumulation of the insoluble mutant SOD1 in an attempt,
perhaps, to remove the misfolded protein responsible for
motor neuronal cell death in these animals. Moreover, by ana-
lyzing the HspB8 effects on the biochemical properties of
mutant SOD1 in motor neuronal cells, we found that HspB8
almost completely counteracts insoluble species formation,
reducing aggregation of mutant SOD1. The HspB8 chaperone
activity also clears monomeric mutant SOD1 from cells, poss-
ibly by assisting its degradation through intracellular degrada-
tive systems. Notably, HspB8 has only minor effects on the
wtSOD1 degradation, and thus this chaperone selectively
recognized only misfolded conformations. This aspect is par-
ticularly relevant in SOD1-linked fALS; in fact, the reduction
of functional SOD1 enzyme might determine an intracellular
loss of protection against neurotoxic-free radical species (6).
With this selective mechanism, HspB8 prevents the loss of
active SOD1 enzyme, exerting a second beneficial effect on
motor neuronal cells. Interestingly, HspB8-induced clearance
of mutant SOD1 does not necessarily require the activity of
the proteasome, since insoluble species, aggregates and mono-
meric forms of mutant SOD1 are removed even during protea-
some inhibition. Therefore, an alternative degradative pathway
must be responsible for the removal of the mutant SOD1 neu-
rotoxic species by HspB8. We found that, both in animal and
cell models of fALS, the APLP system is activated in the pres-
ence of the mutant misfolded G93A-SOD1, since in both cases
autophagosomes have been specifically observed using elec-
tron microscopy analysis. These data strongly agree with pre-
vious observations showing that both proteasome and
autophagy remove mutant SOD1 (32), and suggested that
autophagy is activated in SOD1-linked fALS mice (33,34).
In our study, we demonstrated that HspB8 expression not
only correlates with an increased proteasome-independent
clearance of mutant G93A-SOD1, but also with a robust
increase in intracellular autophagosomes and in the turnover
of the autophagic marker LC3, which is degraded after
APLP activation. HspB8 also heavily modifies the intracellular
distribution of LC3, from a diffuse staining (soluble LC3-I
form) to the typical punctate staining (lipidated LC3-II form,
anchored to the autophagosome membrane to stimulate its
fusion with the lysosome). Finally, we confirmed that HspB8
acts via the APLP, since the APLP inhibitor bafilomycin
counteracted the HspB8-induced degradation of mutant
SOD1 insoluble species. The mechanism(s) by which HspB8
activates mutant SOD1 clearance through autophagy is more
clear on the basis of the present results. Several data showed
TDP-43. Cells have been synchronized at APLP for 15 h using 10 nM of bafilomycin, which was removed 3 h prior to analysis (mock versus mock+HspB8, FL
TDP-43 versus FL TDP-43+HspB8, DC TDP-43 versus DC TDP-43+ HspB8, ∗P , 0.001). (D) Filter retardation assays on NSC34 cells expressing FLAG-
tagged DC TDP-43 in the absence or in the presence of HspB8, in the basal condition or after treatment with 10 mM of MG132 for 24 h, or 10 nM of bafilomycin
for 24 h. The histogram represents a quantification of the filter retardation assay (from three different replicates) (∗P , 0.001, +HspB8 versus 2HspB8; §P,
0.001, +Mg132+HspB8 versus +Mg132; 8P , 0.001, +HspB8+bafilo versus +HspB8).
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that HspB8 forms stable complexes with Bag3 required to
stimulate autophagy (11,12). Notably, Bag3 knock-out mice
show muscular loss (35), and mutant Bag3 has been associated
with muscular dystrophy and peripheral neuropathy (18).
These findings suggest that HspB8, together with its partner
Bag3, may play an important role for the survival of motor
neurons and muscular cells. The interaction domain between
HspB8 and Bag-3 has been recently fully characterized (36),
and the pathway utilized by HspB8 to target misfolded pro-
teins to the autophagic degradation has been unraveled in
muscle cells (25). The HspB8 complexes with Bag-3 and sub-
sequently recruits Hsc70 and CHIP; this heteromeric complex
recognizes the misfolded protein assisted by p62 and activates
autophagy (25). Interestingly, Hsc70 has been found to be
highly enriched in mutant SOD1 in detergent-insoluble frac-
tions from the spinal cord of tg fALS mice at different
stages of disease (37). Finally, CHIP, a component of the
HspB8/Bag3/Hsc70/CHIP, is a well-known interactor of the
mutant SOD1 (38). It has also been demonstrated that ubiqui-
tinated Hsc70 induces degradation of mutant SOD1 by inter-
acting with CHIP (38).
The immunoprecipitation, performed using an anti-SOD1
antibody in NSC34 immortalized motor neurons with autopha-
gosome formation blocked by 3-MA, definitely demonstrated
that mutant SOD1 clearance with HspB8 is mediated by autop-
hagy. In fact, only a small amount of HspB8 or Bag3 can be
found bound to mutant SOD1 in the basal conditions, when
misfolded SOD1 is probably recognized and immediately tar-
geted to autophagic degradation. In fact, inhibition of autopha-
gosome assembly, which prevents misfolded mutant SOD1
clearance via autophagy, leads to its accumulation in the mul-
tiheteromeric complex containing not only HspB8, but also
Bag3, Hsc70 and CHIP; these proteins are all required for mis-
folded protein insertion into the autophagosome (25). Our data
thus strongly suggest that HspB8 has a key role by acting as
the first element of the entire system. These complementary
data provide a molecular explanation of the HspB8 action
on mutant SOD1 and reinforce the hypothesis that a reduction
in the autophagic flux might be responsible for misfolded
protein accumulation. Thus, HspB8 plays an essential role in
motor neuronal disease, since the simple over-expression of
one of the components (HspB8) of the autophagy-mediated
degradative system (HspB8/Bag3/Hsc70/CHIP) seems to be
sufficient to restore an active process. The HspB8 in this
view has to be considered the limiting factor of the process.
These data may also explain why anterior horn spinal cord
motor neurons of tg ALS mice over-expressed HspB8; poss-
ibly, this is an attempt to eliminate the neurotoxic misfolded
protein via autophagy, or response to proteasomal inhibition.
The same mechanism can also take place in the astrocytes,
which, at ES, also over-expressed HspB8.
We also found, in agreement with previous data, that
TDP-43 lacking the C-terminal domain (DC TDP-43) misloca-
lized in the cell cytoplasm (28,29), generating oligomeric
insoluble forms. Our data demonstrate that HspB8 completely
counteracts the formation of oligomeric species of DC
TDP-43, and greatly reduces the total amount of insoluble
species of DC TDP-43 in motor neurons. Even in the case of
TDP-43, our data proved that HspB8 activity is mediated by
autophagy. These observations are in line with data showing
that autophagy is involved in basal TDP-43 metabolism; in
fact, autophagy inhibition increases TDP-43 accumulation,
while rapamycin, an inhibitor of mTOR (a key protein in
autophagy regulation), restores TDP-43 nuclear localization,
preventing its cytoplasmic accumulation (39). In our study,
the APLP inhibition resulted in the loss of HspB8-mediated
degradation of TDP-43 insoluble species.
Thus, HspB8 chaperone activity might be implicated in the
degradation of several types of neurotoxic proteins accumulat-
ing in TDP-43-positive aggregates in most of the cases of
sporadic ALS, in some fALS not linked to SOD1 mutations,
as well as in frontotemporal dementia (2,4,5). A screening
on genes involved in fALS or sALS has demonstrated that,
among others, HspB8 expression is significantly increased in
autoptic lumbar spinal cord from both sALS and SOD1-linked
fALS cases (40). Unfortunately, the study did not consider
whether this increased HspB8 mRNA expression is confined
to spinal cord motor neurons in ALS patients. Our immunohis-
tochemical study in tg G93A-SOD1 mice spinal cord clearly
indicates that HspB8 over-expression occurs in motor neur-
onal cells in response to mutant SOD1 accumulation. Thus,
both animal model and sALS patient data strongly support
the hypothesis that HspB8 might be activated in response to
the aberrant behavior of mutant misfolded proteins in motor
neurons, in the attempt to counteract their neurotoxicity. Inter-
estingly, it has been recently reported that the expression in
primary culture of motor neurons of the HspB8 (K141N and
K141E) mutant lacking chaperone activity correlates with
neurite degeneration (41), and this effect is specific for
spinal cord motor neurons. HspB8 also counteracts the for-
mation of inclusion bodies containing pre-amyloid oligomer
intermediates (amyloid oligomer) of mutant HspB5
(alpha-b-crystallin), a small Hsp that causes desmin-related
cardiomyopathy (DRM) (42). In this case, HspB8 significantly
improves cardiac function and survival of R120G tg mice
expressing the mutant HspB5 (43).
Overall, these results indicate that the pharmacological
modulation of the HspB8 expression in motor neurons may
have an important implication in unraveling the molecular
mechanisms involved both in fALS and in sALS.
MATERIALS AND METHODS
Materials and additional methods are available in the Sup-
plementary Material.
Plasmids
pCDNA3-wtSOD1 and pCDNA3-G93A-SOD1 express
wtSOD1 and mutant G93A-SOD1 (44). pECFP-wtSOD1 and
pECFP-G93A-SOD1 express wt and mutant human SOD1
tagged with cyan fluorescent protein (CFP) (6). YFPu expresses
a CL1-tagged YFP, a proteasome activity reporter protein
(6,16). pEGFP-wtSOD1 and pEGFP-G93A-SOD1 express the
green FP (GFP)-tagged wt and mutant SOD1 (see Supplementary
Material for details). pCNEO-cMyc-HspB8 expresses the rat
HspB8 (from J. Landry, Canada) (45). pCIHspB8-K141N and
pCIHspB8-K141E express HspB8 with Lysine 141 changed
to asparagine or glutamate, respectively (from S.C., The
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Netherlands) (10). pGL3-enhancer and pRL-TK are from
Promega (Madison, WI, USA); pCMVb and pEGFP-N1 are
from Clontech Lab (Mountain View, CA, USA). promB8, gener-
ated in our laboratory, contains the firefly luciferase cDNA under
the control of a23000/+523 human HspB8 promoter region (see
Supplementary Material for details). pFLAG-FL TDP-43 and
pFLAG-DC TDP-43 express FLAG-tagged wt full-length
human TDP-43 and a C-terminus truncated form (from
E. Buratti, Italy) (29). pEGFP-LC3 expresses a GFP-tagged rat
LC3 (from T. Yoshimori, Japan) (46).
Cell cultures and transfection
The immortalized motor neuronal cell line, NSC34 (14), has been
routinely maintained and transfected [Lipofectamin (Invitrogen)/
transferrin (Sigma) 2:1] as previously described (15).
NSC34 stable-transfected cell lines (from M.T. Carrı`, Italy)
express myc-tagged human wtSOD1 or G93A-SOD1 and have
been routinely maintained as described by Ferri et al. (47).
Animals
Transgenic SOD1G93A mice on C57BL/6JOlaHsd (C57/
G93A) genetic background and corresponding non-tg litter-
mates were used. Mice were maintained as previously
described (48) and according to the institutional guidelines,
that are in compliance with national (D.L. no. 116, G.U.
suppl. 40, 18 February 1992, Circolare No. 8, G.U., 14 July
1994) and international laws and policies (EEC Council Direc-
tive 86/609, OJ L 358, 1, 12 December 1987; NIH Guide for
the Care and use of Laboratory Animals, U.S. National
Research Council, 1996).
To evaluate disease stages, starting from the 14th week of
age and twice a week, mice were tested for deficit in grip
strength and rotarod performance by the same operator. The
onset of symptoms was considered when the mice showed
the first impairment in grip strength. Body weight loss was
also followed. Mice have been sacrificed at the presympto-
matic (PS, 12 weeks), clinical symptomatic (CS, 18 weeks
on the average) and end stage (ES, 24–25 weeks on the
average) of the progression of the motor dysfunction.
Immunohistochemistry on mice spinal cord sections
Sample preparation is described in the Supplementary
Material. The following mice were analyzed (n ¼ 3 per
group and per age): non-tg, transgenic G93A-SOD1, trans-
genic wtSOD1 at PS, CS, ES ages of disease progression,
using as primary antibodies: rabbit polyclonal antibody
against HspB8 (from J. Landry, Canada; dilution 1:200),
mouse monoclonal anti-human SOD1 (MBL, Japan; dilution
1:3000) and mouse monoclonal anti-GFAP to detect astrocytes
(Invitrogen, 1:2500), revealed by secondary biotinylated anti-
sera (goat anti-rabbit and horse anti-mouse, Vector, 1:200) and
the Avidin-Biotin-peroxidase Complex (ABC, Vector), using
diaminobenzidine as chromogen.
For immunofluorescence secondary antibodies conjugated
to different fluorochromes (goat anti-rabbit Alexa 488, Invitro-
gen, 1:200; donkey anti-mouse CY3, Jackson, 1:1400) were
used to visualize HspB8, SOD1 and GFAP, whereas the
biotinylated Lycopersicon esculentum agglutinin (LEA,
1:2000; Vector Laboratories) revealed by streptavidin-RedX
(Invitrogen) was used for the detection of microglia. Samples
were analyzed with a TCS NT confocal laser scanning micro-
scope (Leica Lasertecknik GmbH, Heidelberg, Germany)
equipped with a 75 mW Kripton/Argon mixed gas laser.
Control sections processed without the primary antisera
gave no immunostaining.
Fluorescence, immunofluorescence and microscopy on
NSC34 cells
Sample preparation is described in the Supplementary
Material. To analyze SOD1s, TDP-43s, HspB8 and ubiquitin
[primary antibodies: mouse monoclonal anti-FLAG (Sigma),
1:200 in milk, rabbit polyclonal anti-HspB8 antibody, 1:200
in milk, mouse monoclonal anti-ub (Santa Cruz), 1:200 in
milk; secondary antibody: Alexa 488 anti-rabbit, Alexa 488
anti-mouse and Alexa 594 anti-mouse (Invitrogen), 1:1000
in milk] were used an Axiovert 200 microscope (Zeiss Instr.,
Oberkochen, Germany) combined with a Photometric Cool-
Snap CCD camera (Ropper Scientific, Trenton, NJ, USA).
Images were processed using Metamorph software (Universal
Imaging, Downingtown, PA, USA).
Western blot analysis and filter retardation assay
Western blot analysis has been performed as previously
described (6) and details are summarized in Supplementary
Material. The following primary and secondary antibodies
were used: (i) for YFPu, mouse monoclonal anti-GFP
(Zymed, San Francisco, CA, USA; 1:1000 in milk); (ii) for
SOD1, rabbit polyclonal anti-Cu/Zn superoxide dismutase
SOD1 (SOD-100; Assay Designs; 1:1000 in milk); (iii) for
TDP-43, mouse monoclonal anti-FLAG (Sigma; 1:1000 in
milk), (iv) for Actin, goat polyclonal anti-Actin (Actin I-19;
Santa Cruz; 1:1000 in milk); (v) the rabbit polyclonal antibody
against HspB8 (from J. Landry; 1:1000 in milk) or (vi) the
mouse monoclonal c-Myc (9E10) (Santa Cruz; 1:1000 in
milk) for HspB8; (vii) for GFP-SOD1s, the peroxidase-labeled
goat Anti-GFP (Vector Laboratories; 1:5000 in TBS-T); (ix)
the mouse monoclonal anti-ub (Santa Cruz; 1:1000 in milk)
for ubiquitin; goat anti-rabbit, goat anti-mouse and donkey
anti-goat peroxidase-conjugated secondary antibodies (Santa
Cruz; 1:5000 in TBS-T).
Filter retardation assay was performed on a 0.2 mm cellu-
lose acetate membrane (Whatman, Dassel, Germany) as pre-
viously described (6) and details are summarized in
Supplementary Material. Slot blots were probed as described
for western blots. The optical intensity of the spots was ana-
lyzed using NIH ImageJ software.
mRNA expression analysis
RT–PCR and real-time PCR have been performed as
previously described (49–51) and details are summarized in
Supplementary Material. Total RNA from lumbar spinal
cord of mice was obtained following ethically approved proto-
cols. Each sample was analyzed in duplicate and HspB8
values were then normalized with those of GAPDH.
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Sample preparation is described in the Supplementary
Material. The antibodies utilized to recognize the multihetero-
meric complex of SOD1, HspB8 and other proteins were the
following: anti-Cu/Zn superoxide dismutase SOD1
(SOD-100; Assay Designs) rabbit polyclonal antibody for
immunoprecipitation and SOD1 detection in western blot,
anti-c-myc (9E10; Santa Cruz) mouse monoclonal antibody
recognizing transfected HspB8, anti-Bag3 (Abcam) rabbit
polyclonal antibody, anti-Hsc70 (Stressgen) rabbit polyclonal
antibody, anti-CHIP (Calbiochem) rabbit polyclonal antibody.
Transcriptional activity
Transcriptional activity has been performed as previously
described (20) using either the LucLite Kit from Perkin
Elmer (Waltham, MA, USA) normalized with b-galactosidase
assay or the Dual Luciferase Assay System (Promega) (see
Supplementary Material for details).
Cytofluorimetric analysis
Cytofluorimetric analysis was performed on GFP-LC3 or
GFP-G93A-SOD1 transfected NSC34 cells (see Supplemen-
tary Material for details). GFP fluorescence was detected
using FACS Calibur (BD Pharmingen) and results analyzed
using CellQuest (BD Pharmigen) software.
Statistical analysis
Statistical analysis has been performed using one-tailed Stu-
dent’s t-test for two group comparisons and one-way
ANOVA for three or more group comparisons using the
PRISM software (GraphPad, San Diego, CA, USA).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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